Introducing AcadeMab Biomedical, a game-changer in the mRNA vaccine world! Building on the cutting-edge cationic lipid technology developed at the Academia Sinica by renowned scientist Han-Chung Wu, AcadeMab is on track to revolutionize mRNA vaccines for Dengue fever. 
 
They’ve just won the prestigious Moderna Taiwan mRNA Innovation Award this year, and are targeting clinical trials by 2026! But that's not all—AcadeMab aims to build a local lipid supply chain in Taiwan, ensuring future growth in nucleic acid vaccines and therapies!
 
As mRNA technology continues to reshape infectious disease, cancer treatments, gene therapies, and immunotherapies, AcadeMab is set to become a leader in this transformative era of medicine! 
 
Stay connected with #Globalbio for the latest in biotech and medical innovations! 
 
#mRNA #DengueVaccine #BiotechInnovation #ModernaInnovationAward #CationicLipid #NucleicAcidTherapy #Globalbio #FutureOfMedicine